Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | NRAS G12C |
Gene Variant Detail | |
Relevant Treatment Approaches | MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor PI3K Inhibitor (Pan) PIK3CA inhibitor RAS Inhibitor (Pan) |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Unknown status | NLD | 0 |
NCT05726864 | Phase Ib/II | ELI-002 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) | Recruiting | USA | 0 |
NCT05638698 | Phase II | Balstilimab + QS21 + TG01 QS21 + TG01 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) | Active, not recruiting | USA | 0 |